Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection site pain comparison of semaglutide versus dulaglutide in healthy volunteers
NL-OMON48004Phase 4Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide and dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Intensity of injection site pain. Started Dec 2019; status: active, not recruiting.
02
Drugs
semaglutidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON48004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48004.